Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Estrella Immunopharma ( (ESLA) ) just unveiled an update.
Estrella Immunopharma, Inc. has appointed Dr. Cheng Liu as Director, President, and CEO with an ‘at will’ employment agreement offering a $250,000 annual salary, bonus potential, and equity incentives. The contract allows flexibility for termination and offers severance packages based on the circumstances, highlighting the company’s strategic focus on aligning leadership performance with financial and operational goals.
Find detailed analytics on ESLA stock on TipRanks’ Stock Analysis page.